ClinicalTrials.gg
Sign In

Drug

Luvometinib clinical trials

Also written FCN-159.

studies test it
13
open now
11
in phase 3
2
first study started
2021

Keep track of what changes. Save the luvometinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

Luvometinib
6

Development codes

FCN-159
7

Combined with it in one product

luvometinib + anlotinib
1
FCN-159+anlotinib
1

Studies by the year they started

13 studies that test it; most in 2026 (6)

Studies that test luvometinib, by start year
YearStudies
20211
20232
20241
20253
20266

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
9
Phase 3
2
No phase
2

What it is tested for

Each study’s main condition, where its own words name it.

Histiocytosis, Langerhans-Cell
4
Neurofibromatosis 1
3
Neurofibromatosis 2
2
Glioma
1
Neoplasm Metastasis
1
Nerve Sheath Neoplasms
1

Who runs them

Industry 6 · Other 7

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (6) · Beijing Tiantan Hospital (2) · West China Second University Hospital (2) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Xuanwu Hospital, Beijing (1)

Often tested with

Tested in the same studies.

Serplulimab (2) · AZD 6244 (1) · Anlotinib (1)

Studies

Open first, then newest update. How each study uses luvometinib is read from its arms, and is right about nine times in ten.

Testing it · 13

Codes

What other systems call luvometinib · ClinicalTrials.gg INT016057

  • UNII (FDA) B2DYT4V89XLUVOMETINIBConfirmed FDA, Wikidata
  • Wikidata Q135746264luvometinibConfirmed FDA, Wikidata
  • NCI Thesaurus C172382LuvometinibOne source FDA
  • DrugBank DB21696One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.